Skip to main content
. 2007 Nov 15;1:13. doi: 10.1186/1753-2000-1-13

Figure 4.

Figure 4

Range of plausible projections: expenditures under extreme case scenarios, 2001–2012. a, b: "High Extreme" Case; c, d: Base Case modified "LisDEX without clinical advantage over MPH-MR"; e, f: "Low Extreme" Case; left: England; right: Germany. MPH: methylphenidate; IR: immediate-release formulations (RitalinR, branded generics [EquasymR, MedikinetR], generics; FocalinR); MR: modified-release formulations (ConcertaR XL, EquasymR XL, MedikinetR retard, FocalinR XR; MPH-Patch: transdermal system (DaytranaR); LisDEX: lisdexamphetamine (NRP104); Nonstimulants: ATX, atomoxetine (StratteraR), ARM, armodafinil (SparlonR); DEX: dexamphetamine (England only).